Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 39 results for vinorelbine

  1. Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA531)

    Evidence-based recommendations on pembrolizumab (Keytruda) for untreated PD-L1-positive metastatic non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    18 July 2018

    Sections for TA531

  2. Pemetrexed for the maintenance treatment of non-small-cell lung cancer (TA190)

    Evidence-based recommendations on pemetrexed disodium (Alimta) for the maintenance treatment of non-small-cell lung cancer.

    Technology appraisal guidance
    Last updated
    10 August 2017
    View recommendations

    Sections for TA190

  3. Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma (TA818)

    Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated unresectable malignant pleural mesothelioma in adults.

    Technology appraisal guidance
    Published
    17 August 2022
    View recommendations

    Sections for TA818

  4. Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (TA770)

    Evidence-based recommendations on pembrolizumab (Keytruda) with carboplatin and paclitaxel for adults with untreated metastatic squamous non-small-cell lung cancer.

    Technology appraisal guidance
    Published
    9 February 2022
    View recommendations

    Sections for TA770

  5. Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer (TA876)

    Evidence-based recommendations on nivolumab (Opdivo) with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    22 March 2023
    View recommendations

    Sections for TA876

  6. Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (TA683)

    Evidence-based recommendations on pembrolizumab (Keytruda) with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (NSCLC) in adults whose tumours have no epidermal growth factor receptor (EGFR)- or anaplastic lymphoma kinase (ALK)-positive mutations.

    Technology appraisal guidance
    Published
    10 March 2021
    View recommendations

    Sections for TA683

  7. Past appeals and decisions

    Past technology appraisal appeals and decisions

  8. Nivolumab with ipilimumab for untreated non-small-cell lung cancer that has a high tumour mutational burden [ID1187]

    Discontinued Reference number: GID-TA10234

    Technology appraisal guidance
    Discontinued

  9. Treatments for non-small-cell lung cancer [ID6234]

    Discontinued Reference number: GID-TA11289

    Technology appraisal guidance
    Discontinued

  10. Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]

    In development Reference number: GID-TA10900 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Pembrolizumab for untreated PD-L1 positive non-small-cell lung cancer with at least 1% tumour proportion score [ID1247]

    Discontinued Reference number: GID-TA10271

    Technology appraisal guidance
    Discontinued

  12. Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer (TA411)

    Evidence-based recommendations on necitumumab (Portrazza) for treating locally advanced or metastatic epidermal growth factor receptor (EGFR)-expressing squamous non-small-cell lung cancer in adults who have not had chemotherapy.

    Technology appraisal guidance
    Published
    28 September 2016
    View recommendations

    Sections for TA411

  13. Guidance on the use of vinorelbine for the treatment of advanced breast cancer (TA54)

    This guidance has been updated and replaced by NICE guideline CG81.

    Withdrawn guidance

  14. Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer (TA227)

    Evidence-based recommendations on erlotinib (Tarceva) for the maintenance treatment of non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    29 June 2011
    View recommendations

    Sections for TA227

  15. Docetaxel, paclitaxel, gemcitabine and vinorelbine for the treatment of non-small cell lung cancer (TA26)

    This guidance has been replaced by NICE guideline CG24 [Replaced by NICE guideline CG121].

    Withdrawn guidance